Frontline Nilotinib in Pediatric Chronic Myeloid Leukemia: An Interim Analysis of SCCCG[PLUS]-CML 2023

Background: Evidence on the depth of molecular response and long-term tolerability of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase (CML-CP) remains limited. Methods: Children with newly diagnosed BCR::ABL1-positive CML-CP received nilotinib 230 mg/m2 twice daily in a prospective multicenter cohort. BCR::ABL1 on the International Scale (IS) was assessed at scheduled visits; major molecular response (MMR), MR4, and MR4.5 were summarized among patients with data at cycles 3, 6, and 12. Adverse events were graded using Common Terminology Criteria for Adverse Events version 5.0. Nilotinib trough concentrations were assessed in 54 patients using morning predose blood samples analyzed at a specialized third-party clinical laboratory. Results: Ninety-two children were included (median age, 10.3 years [IQR, 7.6–12.5]); 64 (69.6%) were male. MMR was recorded in 22/78 (28.2%), 37/64 (57.8%), and 40/50 (80.0%) evaluable patients at cycles 3, 6, and 12, respectively. At cycle 12, 19/50 (38.0%) had MR4 and 15/50 (30.0%) had MR4.5. At a median follow-up of 1.79 years (IQR, 1.09–2.83), the estimated 2-year event-free survival was 96.4% (95% CI, 86.1–99.1%). Common adverse events included ALT elevation (60/90, 66.7%), myelosuppression (43/87, 49.4%), hyperbilirubinemia (35/89, 39.3%), and rash (29/92, 31.5%). At cycle 6, nilotinib trough concentration showed a modest inverse correlation with BCR::ABL1 transcript levels (Spearman ρ = −0.329, p = 0.044). Conclusions: Frontline nilotinib produced clinically meaningful molecular responses in evaluable pediatric patients with CML-CP. The observed association between trough concentration and molecular response was modest and exploratory and requires prospective validation.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-16
DOI
https://doi.org/10.3390/biomedicines14112645
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Frontline Nilotinib in Pediatric Chronic Myeloid Leukemia: An Interim Analysis of SCCCG[PLUS]-CML 2023

Qiao-Ru Li, X. Zhang, Li‐Bin Huang, W Wan et al.
1 links
Biomedicines
Chronic Myeloid Leukemia Treatments
article

Frontline Nilotinib in Pediatric Chronic Myeloid Leukemia: An Interim Analysis of SCCCG[PLUS]-CML 2023

Qiao-Ru Li, X. Zhang, Li‐Bin Huang, W Wan, Xin Tian, Liuhua Liao, 林丽敏, 何飞, Min-Hui Zeng, Huirong Mai, Xue-Qun Luo, Haixia Guo, Xiaoyan Yang, Hongying Wei, Fan Zhong, Xing‐Jiang Long, Cong Liang, Xiaobo Zhou, Biyun Guo, Dun-hua Zhou, Hao-Yan Ren, Ya-Wei Zou, Qi-Wen Chen, Hui-Qin Chen, Wei-Na Zhang, Xiu-Ya Huang, He-Kui Lan, Wen-Jie Xiong, Li-Li Liu, Qiang Fu, Li-Hua Yang
article en

Abstract

Background: Evidence on the depth of molecular response and long-term tolerability of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase (CML-CP) remains limited. Methods: Children with newly diagnosed BCR::ABL1-positive CML-CP received nilotinib 230 mg/m2 twice daily in a prospective multicenter cohort. BCR::ABL1 on the International Scale (IS) was assessed at scheduled visits; major molecular response (MMR), MR4, and MR4.5 were summarized among patients with data at cycles 3, 6, and 12. Adverse events were graded using Common Terminology Criteria for Adverse Events version 5.0. Nilotinib trough concentrations were assessed in 54 patients using morning predose blood samples analyzed at a specialized third-party clinical laboratory. Results: Ninety-two children were included (median age, 10.3 years [IQR, 7.6–12.5]); 64 (69.6%) were male. MMR was recorded in 22/78 (28.2%), 37/64 (57.8%), and 40/50 (80.0%) evaluable patients at cycles 3, 6, and 12, respectively. At cycle 12, 19/50 (38.0%) had MR4 and 15/50 (30.0%) had MR4.5. At a median follow-up of 1.79 years (IQR, 1.09–2.83), the estimated 2-year event-free survival was 96.4% (95% CI, 86.1–99.1%). Common adverse events included ALT elevation (60/90, 66.7%), myelosuppression (43/87, 49.4%), hyperbilirubinemia (35/89, 39.3%), and rash (29/92, 31.5%). At cycle 6, nilotinib trough concentration showed a modest inverse correlation with BCR::ABL1 transcript levels (Spearman ρ = −0.329, p = 0.044). Conclusions: Frontline nilotinib produced clinically meaningful molecular responses in evaluable pediatric patients with CML-CP. The observed association between trough concentration and molecular response was modest and exploratory and requires prospective validation.

BiomedicinesVol. 14(11)
Sun Yat-sen University (CN), Guangxi Medical University (CN), Hunan Normal University (CN), Guangdong Medical College (CN), Shantou University (CN), First Affiliated Hospital of Xiamen University (CN), Liuzhou General Hospital (CN), Kunming Children's Hospital (CN), Sun Yat-sen Memorial Hospital (CN), First Affiliated Hospital of Guangzhou Medical University (CN), Nanfang Hospital (CN), Guangzhou Women and Children Medical Center (CN), Zhongshan People's Hospital (CN), Affiliated Hospital of Guizhou Medical University (CN), Zhujiang Hospital (CN), Second Affiliated Hospital of Shantou University Medical College (CN), First Affiliated Hospital of GuangXi Medical University (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), The Second Nanning People's Hospital (CN), Huizhou Central People's Hospital (CN), Wuhan Children's Hospital (CN), Jiangxi Provincial Children's Hospital (CN), Third Affiliated Hospital of Sun Yat-sen University (CN), Hunan Provincial People's Hospital (CN), Shenzhen Children's Hospital (CN), Second Xiangya Hospital of Central South University (CN), First Affiliated Hospital of Nanchang University (CN), Huazhong University of Science and Technology (CN), Southern Medical University (CN), Guangzhou Medical University (CN)
Basic and Applied Basic Research Foundation of Guangdong Province
Good health and well-being
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon